Efficacy of a new bivalent vaccine of porcine circovirus type 2 and Mycoplasma hyopneumoniae (Fostera™ PCV MH) under experimental conditions

Vaccine

Volumn 34, Issue 2, 2016, Pages 270-275

  Park, Changhoon ^a   Jeong, Jiwoon ^a   Choi, Kyuhyung ^a   Chae, Chanhee ^a  

^a Seoul National University   (South Korea)

Author keywords

Bivalent vaccine; Mycoplasma hyopneumoniae; Porcine circovirus type 2; Porcine circovirus associated disease; Porcine respiratory disease complex

Indexed keywords

BACTERIAL VACCINE; BIVALENT MYCOPLASMA HYOPNEUMONIAE VACCINE; BIVALENT PORCINE CIRCOVIRUS TYPE 2 VACCINE; GAMMA INTERFERON; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS VACCINE; VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL SHEDDING; CIRCOVIRIDAE INFECTION; CLINICAL OBSERVATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOHISTOCHEMISTRY; LUNG LESION; MYCOPLASMA HYOPNEUMONIAE; MYCOPLASMAL PNEUMONIA OF SWINE; NONHUMAN; NOSE SMEAR; PHASE 2 CLINICAL TRIAL; PORCINE CIRCOVIRUS 2; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SECRETORY CELL; SEROLOGY; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; VACCINATION; VIRUS NEUTRALIZATION; VIRUS SHEDDING; ANIMAL; BLOOD; CIRCOVIRIDAE INFECTIONS; CIRCOVIRUS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; LUNG; LYMPH NODE; MONONUCLEAR CELL; MYCOPLASMA INFECTIONS; PATHOLOGY; PIG; RANDOMIZATION; SECRETION (PROCESS); SWINE DISEASES; TREATMENT OUTCOME; VETERINARY; VIREMIA;

ANIMAL EXPERIMENTATION; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BACTERIAL SHEDDING; BACTERIAL VACCINES; CIRCOVIRIDAE INFECTIONS; CIRCOVIRUS; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LUNG; LYMPH NODES; MYCOPLASMA HYOPNEUMONIAE; MYCOPLASMA INFECTIONS; RANDOM ALLOCATION; SWINE; SWINE DISEASES; TREATMENT OUTCOME; VACCINES, COMBINED; VIRAL VACCINES; VIREMIA;

EID: 84955079415     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.11.034     Document Type: Article

References (35)

1. Kim J., Chung H-K., Chae C. Association of porcine circovirus 2 with porcine respiratory disease complex. Vet J 2003, 166:251-256.
2. Opriessnig T., Thacker E.L., Yu S., Fenaux M., Meng X-J., Halbur P.G. Experimental reproduction of postweaning multisystemic wasting syndrome in pigs by dual infection with Mycoplasma hyopneumoniae and porcine circovirus type 2. Vet Pathol 2004, 41:624-640.
3. Chae C. Postweaning multisystemic wasting syndrome: a review of aetiology, diagnosis and pathology. Vet J 2004, 168:41-49.
4. Chae C. A review of porcine circovirus 2-associated syndromes and diseases. Vet J 2005, 169:326-336.
5. Chae C. Porcine circovirus type 2 and its associated disease in Korea. Virus Res 2012, 164:107-113.
6. Vicca J., Stakenborg T., Maes D., Butaye P., Peeters J., de Kruif A., et al. In vitro susceptibilities of Mycoplasma hyopneumoniae field isolates. Antimicrob Agents Chemother 2004, 48:4470-4472.
7. Barton M.D. Impact of antibiotic use in the swine industry. Curr Opin Microbiol 2014, 19:9-15.
8. Gagnon C.A., del Castillo J.R., Music N., Fontaine G., Harel J., Tremblay D. Development and use of a multiplex real-time quantitative polymerase chain reaction assay for detection and differentiation of Porcine circovirus-2 genotypes 2a and 2b in an epidemiological survey. J Vet Diagn Invest 2008, 20:545-558.
9. Wasilk A., Callahan J.D., Christopher-Hennings J., Gay T.A., Fang Y., Dammen M., et al. Detection of U.S., Lelystad, and European-like porcine reproductive and respiratory syndrome viruses and relative quantitation in boar semen and serum samples by real-time PCR. J Clin Microbiol 2004, 42:4453-4461.
10. Dubosson C.R., Conzelmann C., Miserez R., Boerlin P., Frey J., Zimmermann W., et al. Development of two real-time PCR assays for the detection of Mycoplasma hyopneumoniae in clinical samples. Vet Microbiol 2004, 102:55-65.
11. Seo H.W., Park S-J., Park C., Chae C. Interaction of porcine circovirus type 2 and Mycoplasma hyopneumoniae vaccines on dually infected pigs. Vaccine 2014, 32:2480-2486.
12. Van Reeth K., Nauwynck H., Pensaert M. A potential role for tumour necrosis factor-α in synergy between porcine respiratory coronavirus and bacterial lipopolysaccharide in the induction of respiratory disease in pigs. J Med Microbiol 2000, 49:613-620.
13. Marchioro S.B., Sacristan R.D.P., Michiels A., Haesebrouck F., Concericao F.R., Dellagostin O.A., et al. Immune responses of a chimeric protein vaccine containing Mycoplasma hyopneumoniae antigens and LTB against experimental M. hyopneumoniae infection in pigs. Vaccine 2014, 32:4689-4694.
14. Beaver B.V., Reed W., Leary S., McKiernan B., Bain F., Schultz R., et al. 2000 Report of the AVMA panel on euthanasia. J Am Vet Med Assoc 2001, 218:669-696.
15. Seo H.W., Han K., Oh Y., Park C., Chae C. Efficacy of a reformulated inactivated chimeric PCV1-2 vaccine based on clinical, virological, pathological and immunological examination under field conditions. Vaccine 2012, 30:6671-6677.
16. Gagnon C.A., Del-Castillo J.R., Music N., Fontaine G., Harel J., Tremblay D. Development and use of a multiplex real-time quantitative polymerase chain reaction assay for detection and differentiation of Porcine circovirus-2 genotypes 2a and 2b in an epidemiological survey. J Vet Diagn Invest 2008, 20:545-558.
17. Kurth K.T., Hsu T., Snook E.R., Thacker E.L., Thacker B.J., Minion F.C. Use of a Mycoplasma hyopneumoniae nested polymerase chain reaction test to determine the optimal sampling sites in swine. J Vet Diagn Invest 2002, 14:463-469.
18. Pogranichnyy R.M., Yoon K.J., Harms P.A., Swenson S.L., Zimmerman J.J., Sorden S.D. Characterization of immune response of young pigs to porcine circovirus type 2 infection. Viral Immunol 2000, 13:143-153.
19. Park C., Oh Y., Seo H.W., Han K., Chae C. Comparative effects of vaccination against porcine circovirus type 2 (PCV2) and porcine reproductive and respiratory syndrome virus (PRRSV) in a PCV2-PRRSV challenge model. Clin Vaccine Immunol 2013, 20:369-376.
20. Bandrick M., Pieters M., Pijoan C., Molitor T.W. Passive transfer of maternal Mycoplasma hyopneumoniae-specific cellular immunity to piglet. Clin Vaccine Immunol 2008, 15:540-543.
21. Diaz I., Mateu E. Use of ELISPOT and ELISA to evaluate IFN-γ, IL-10 and IL-4 responses in conventional pigs. Vet Immunol Immunopathol 2005, 106:107-112.
22. Thacker E.L., Thacker B.J., Kuhn M., Hawkins P.A., Waters W.R. Evaluation of local and systemic immune responses induced by intramuscular injection of a Mycoplasma hyopneumoniae bacterin to pigs. Am J Vet Res 2000, 61:1384-1389.
23. Kim J., Chae C. Expression of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 in porcine circovirus 2-induced granulomatous inflammation. J Comp Pathol 2004, 131:121-126.
24. Kwon D., Chae C. Detection and localization of Mycoplasma hyopneumoniae DNA in lungs from naturally infected pigs by in situ hybridization using a digoxigenin-labeled probe. Vet Pathol 1999, 36:308-313.
25. Kim D., Kim C.H., Han K., Seo H.W., Oh Y., Park C., et al. Comparative efficacy of commercial Mycoplasma hyopneumoniae and porcine circovirus 2 (PCV2) vaccines in pigs experimentally infected with M. hyopneumoniae and PCV2. Vaccine 2011, 29:3206-3212.
26. Fort M., Olvera A., Sibila M., Segalés J., Mateu E. Detection of neutralizing antibodies in postweaning multisystemic wasting syndrome (PMWS)-affected and non-PMWS-affected pigs. Vet Microbiol 2007, 125:244-255.
27. Fort M., Fernandes L.T., Nofrarias M., Diaz I., Sibila M., Pujols J., et al. Development of cell-mediated immunity to porcine circovirus type 2 (PCV2) in Caesarean-derived, colostrum-deprived piglets. Vet Immunol Immunopathol 2009, 129:101-107.
28. Meerts P., Van-Gucht S., Cox E., Vandebosch A., Nauwynck H.J. Correlation between type of adaptive immune response against porcine circovirus type 2 and level of virus replication. Viral Immunol 2005, 18:333-341.
29. Meerts P., Misinzo G., Lefebvre D., Nielsen J., Botner A., Kristensen C.S., et al. Correlation between the presence of neutralizing antibodies against porcine circovirus 2 (PCV2) and protection against replication of the virus and development of PCV2-associated disease. BMC Vet Res 2006, 2:6.
30. Park S-J., Seo H.W., Park C., Chae C. Interaction between single-dose Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus vaccines on dually infected pigs. Res Vet Sci 2014, 96:516-522.
31. Martelli P., Terreni M., Guazzetti S., Cavirani S. Antibody response to Mycoplasma hyopneumoniae infection in vaccinated pigs with or without maternal antibodies induced by sow vaccination. J Vet Med B Infect Dis Vet Public Health 2006, 53:229-233.
32. Djordjevic S.P., Eamens G.J., Romalis L.F., Nicholls P.J., Taylor V. Chin J. Serum and mucosal antibody responses and protection in pigs vaccinated against Mycoplasma hyopneumoniae with vaccines containing a denatured membrane antigen pool and adjuvant. Aust Vet J 1997, 75:504-511.
33. Thacker E.L., Thacker B.J., Boettcher T.B., Jayappa H. Comparison of antibody production, lymphocyte stimulation, and protection induced by four commercial Mycoplasma hyopneumoniae bacterins. J Swine Health Prod 1998, 6:107-112.
34. Maes D., Segales J., Meyns T., Sibila M., Pieters M., Haesebrouck F. Control of Mycoplasma hyopneumoniae infections in pigs. Vet Microbiol 2008, 126:297-309.
35. Woolley L.K., Fell S.A., Gonsalves J.R., Raymond B.B.A., Collins D., Kuit T.A., et al. Evaluation of recombinant Mycoplasma hyopneumoniae P97/P102 paralogs formulated with selected adjuvants as vaccines against mycoplasmal pneumonia in pigs. Vaccine 2014, 32:4333-4341.